NCT00732992 - A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

Neoplasm, Malignant

Interventions

DRUG

Sunitinib, Pemetrexed

Sunitinib daily by oral capsule in a continuous daily dosing regimen with pemetrexed every 3 weeks until progression or unacceptable toxicity.

DRUG

Sunitinib, Pemetrexed

Sunitinib daily by oral capsule administered for 2 weeks out of every 3 weeks with pemetrexed every 3 weeks until progression or unacceptable toxicity.

Trial Locations (1)

Unknown

Pfizer Investigational Site, Osakasayama-shi